Alexander A Shtil
Overview
Explore the profile of Alexander A Shtil including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
103
Citations
557
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Polinova A, Serkina A, Volkova M, Gorbunov A, Sannikova E, Gubaidullin I, et al.
Nanotheranostics
. 2025 Mar;
9(1):67-81.
PMID: 40078315
Previously, to obtain antigen-presenting self-assembling protein nanoparticles (SAPN), we developed a biosynthetic platform combining the self-associating peptide LKD and the SUMO protein. In the current work, the immunogenic SUMO was...
2.
Khamidullina A, Yastrebova M, Bruter A, Nuzhina J, Vorobyeva N, Khrustaleva A, et al.
Cell Death Discov
. 2025 Feb;
11(1):62.
PMID: 39955308
Imatinib mesylate (IM) and other BCR-ABL tyrosine kinase inhibitors (BCR-ABLi) are the mainstay of chronic myelogenous leukemia (CML) treatment. However, activation of circumventing signaling pathways and quiescence may limit BCR-ABLi...
3.
Alpatova V, Nguyen M, Rys E, Liklikadze G, Kononova E, Smolyakov A, et al.
Biomater Sci
. 2024 Dec;
13(3):711-730.
PMID: 39704220
The tetrapyrrolic macrocycle as a scaffold for various chemical modifications provides broad opportunities for the preparation of complex multifunctional conjugates suitable for binary antitumor therapies. Typically, illumination with monochromatic light...
4.
Ivanov S, Zgoda V, Isakova V, Trukhanova L, Poroikov V, Shtil A
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682211
Damage of the gastrointestinal mucosa is a major side effect of the anticancer drug 5-fluorouracil (5-FU). Insight into the molecular pathogenesis of 5-FU-induced gut mucositis is expected to justify the...
5.
Shtil A, Chernov K, Tsymbal S
Cancers (Basel)
. 2024 Nov;
16(22).
PMID: 39594722
Dear Editor: [...].
6.
Koroleva O, Kurkin A, Shtil A
Expert Opin Investig Drugs
. 2024 Nov;
33(12):1177-1185.
PMID: 39592955
Introduction: The Hippo signaling governs the expression of genes critically important for cell proliferation and survival. The components of this pathway are considered antitumor drug targets. However, the design of...
7.
Shtil A
Int J Mol Sci
. 2024 Jun;
25(11).
PMID: 38892232
When, in 2022, the asked me to edit the Special Issue, I was quick to propose the title 'Novel Chemical Tools for Targeted Cancer Therapy' [...].
8.
Beloglazkina E, Moiseeva A, Tsymbal S, Guk D, Kuzmin M, Krasnovskaya O, et al.
Molecules
. 2024 Mar;
29(5).
PMID: 38474543
Copper-organic compounds have gained momentum as potent antitumor drug candidates largely due to their ability to generate an oxidative burst upon the transition of Cu to Cu triggered by the...
9.
Borisevich S, Aksinina T, Ilyina M, Shender V, Anufrieva K, Arapidi G, et al.
Cancers (Basel)
. 2024 Feb;
16(4).
PMID: 38398225
Serine-threonine protein kinases of the DYRK and CLK families regulate a variety of vital cellular functions. In particular, these enzymes phosphorylate proteins involved in pre-mRNA splicing. Targeting splicing with pharmacological...
10.
Sedenkova K, Leschukov D, Grishin Y, Zefirov N, Gracheva Y, Skvortsov D, et al.
Pharmaceuticals (Basel)
. 2023 Oct;
16(10).
PMID: 37895970
Tubulin-targeting agents attract undiminished attention as promising compounds for the design of anti-cancer drugs. Verubulin is a potent tubulin polymerization inhibitor, binding to colchicine-binding sites. In the present work, a...